An announcement from Sino Biopharmaceutical ( (HK:1177) ) is now available.
Sino Biopharmaceutical Limited reported a significant financial performance for the year ending December 31, 2024, with a 10.2% increase in revenue to RMB 28.87 billion and a 24.9% rise in profit to RMB 6.36 billion. The company attributed its growth to increased sales of innovative and new products, which accounted for a larger share of revenue compared to the previous year. The Board recommended a final dividend of HK4 cents per share, reflecting the company’s strong financial health and commitment to shareholder returns.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a leading pharmaceutical conglomerate in China, known for its innovative R&D-driven approach. The company offers a wide range of biopharmaceutical and chemical medicines, focusing on therapeutic areas such as oncology, liver diseases, respiratory diseases, and surgery/analgesia. It operates a fully-integrated industrial chain with various R&D platforms, intelligent production operations, and a strong sales system. Listed on the Hong Kong Stock Exchange, Sino Biopharm has been recognized among the ‘Top 50 Global Pharmaceutical Enterprises’ and ‘Asia’s Fab 50 Companies.’
YTD Price Performance: 19.74%
Average Trading Volume: 1,083
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $8.69B
Find detailed analytics on 1177 stock on TipRanks’ Stock Analysis page.